Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2551017 | 0.76 | SLC2A1 (0.31) | LMNAKDM4EPOLB | |
| SCHEMBL2543891 | 0.76 | KDM4E (0.31) | LMNAKDM4EPOLB | |
| SCHEMBL7132590 | 0.75 | MEN1 (0.42) | MEN1KMT2APDE4BPDE4DMAPT | |
| SCHEMBL9581979 | 0.75 | — | — | |
| SCHEMBL5497340 | 0.75 | ALDH1A1 (0.34) | MEN1KMT2AMAPTLMNAKDM4E | |
| SCHEMBL2548441 | 0.74 | HTR1A (0.34) | MEN1KMT2APDE4BPDE4DMAPT | |
| SCHEMBL6015950 | 0.73 | KMT2A (0.50) | MEN1KMT2AMAPTLMNAKDM4E | |
| SCHEMBL2547432 | 0.73 | HTR1A (0.34) | PDE4BRAB9ANPC1LMNAKDM4E | |
| SCHEMBL6236614 | 0.72 | SLC9A1 (0.37) | MEN1KMT2AMAPTUSP2LMNA | |
| SCHEMBL694560 | 0.72 | TNF (0.44) | MEN1KMT2ALMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112521382-A | Aloe-emodin thiazolidinedione compound and preparation method and application thereof | 西南大学 | 2021-03-19 | — | — | CN | claimed |
| US-6747053-B2 | Heteroaryl nitriles | ROCHE PALO ALTO LLC | 2004-06-08 | — | — | US | claimed |
| US-6693098-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIVES CONTAINING CARBAMATE GROUPS ARE USEFUL FOR TREATING THE CONDITIONS ASSOCIATED WITH THE URINARY TRACT, PAIN, INFLAMMATION, RESPIRATORY STATES, EDEMA FORMATION OF HYPOTENSIVE VASCULAR DISEASES | SYNTEX (U.S.A) LLC | 2004-02-17 | — | — | US | claimed |
| US-20030212097-A1 | Heteroaryl nitriles | ROCHE PALO ALTO LLC | 2003-11-13 | — | — | US | claimed |
| EP-1321169-A1 | Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament | Biofrontera Pharmaceuticals AG (DE) | 2003-06-25 | — | — | EP | claimed |
| EP-0966456-B1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2003-04-02 | — | — | EP | claimed |
| EP-0923550-B1 | ACYLAMINOALKENYLENE-AMIDE DERIVATIVES AS NK1 AND NK2 ANTAGONISTS | NOVARTIS AG (CH) | 2002-09-25 | — | — | EP | claimed |
| US-6319917-B1 | NEUROGENIC INFLAMMATION AND TACHYKININ BRONCHOCONSTRICTION INHIBITORS | NOVARTIS AG (CH) | 2001-11-20 | — | — | US | claimed |
| EP-0923550-A1 | ACYLAMINOALKENYLENE-AMIDE DERIVATIVES AS NK1 AND NK2 ANTAGONISTS | Novartis AG (CH) | 1999-06-23 | — | — | EP | claimed |
| US-5863924-A | Aryl pyrimidine derivatives | SYNTEX (U.S.A.) INC. (US) | 1999-01-26 | — | — | US | claimed |
| US-5811452-A | ADMINISTERING WITH PACLITAXEL OR DOXORUBICIN | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-09-22 | — | — | US | claimed |
| WO-1998007694-A1 | ACYLAMINOALKENYLENE-AMIDE DERIVATIVES AS NK1 AND NK2 ANTAGONISTS | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | claimed |
| EP-0540956-B1 | Process for the manufacture of substituted maleimides | HOFFMANN LA ROCHE (CH) | 1997-09-03 | — | — | EP | claimed |
| EP-0540956-A1 | Process for the manufacture of substituted maleimides | F. HOFFMANN-LA ROCHE AG (CH) | 1993-05-12 | — | — | EP | claimed |
| EP-0350403-B1 | (AZA)NAPHTHALENESULTAM DERIVATIVES, PROCESS FOR THEIR PREPARATION AND DRUGS CONTAINING SAME | RHONE-POULENC SANTE (FR) | 1993-01-13 | — | — | EP | claimed |
| US-5036075-A | Serotonin antagonists | RHONE-POULENC SANTE (FR) | 1991-07-30 | — | — | US | claimed |
| US-5021420-A | Antiserotonine agents; central nervous system, gastroin-testinal and cardiovascular disorders | RHONE-POULENC SANTE (FR) | 1991-06-04 | — | — | US | claimed |
| US-4355823-A | Pressure-sensitive or heat-sensitive recording material | CIBA-GEIGY CORPORATION (US) | 1982-10-26 | — | — | US | claimed |
| US-11299513-B2 | Cyclative release of peptidic compounds | CIRCLE PHARMA, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-4254032-A | COLOR FORMERS FOR HEAT SENSITIVE OR PRESSURE SENSITIVE ELEMENTS | CIBA-GEIGY CORPORATION (US) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299513-B2 | Cyclative release of peptidic compounds | VIP, FURIN, PTMS | MEN1 890/4885KMT2A 4453/4885PDE4B 1397/4885 |
| US-20030212097-A1 | Heteroaryl nitriles | UACA, FPR1, GSTA1 | MEN1 1396/4885KMT2A 4691/4885PDE4B 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.